Fish vaccines are crucial tools in aquaculture to prevent infectious diseases, enhancing the health and productivity of fish populations. These vaccines aim to stimulate the fish's immune system, providing protection against specific pathogens. Common fish vaccines include those targeting bacterial, viral, and parasitic infections. They are administered through various methods such as immersion, injection, or oral delivery, depending on the species and disease. Vaccination in aquaculture helps reduce the need for antibiotics and promotes sustainable practices by minimizing disease outbreaks. Key pathogens addressed by fish vaccines include Vibrio species, infectious salmon anemia virus, and various parasites. Research and development continue to advance fish vaccine technology, focusing on improving efficacy, safety, and ease of administration. The aquaculture industry relies on these vaccines to ensure the well-being of fish populations, supporting the global demand for seafood while mitigating the environmental impact of diseases.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States